Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Arcus revenue from Gilead by Year
Arcus revenue from Gilead — License & development services (legacy axis, $M) ($M)
Gilead Sciences Arcus revenue from Gilead: $214M in FY2025, up 3.4% from a year earlier.
Where the FY2025 figure comes from
Source: Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
Reported in Arcus Biosciences (RCUS) Form 10-Q / 10-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arcus revenue from Gilead — License & development services (legacy axis, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 214 | +3.4% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2024 | Dec 31, 2024 | 207 | +176.0% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 75 | – | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Arcus revenue from Gilead ($M), annual FY2023–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus-rev-gilead-lic
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.